

For Immediate Release

**PluroGen Therapeutics, Inc. Announces**

**Patient Enrollment Completed in Phase II Clinical Trial  
to Treat Mild Infections in Diabetic Foot Ulcers**

Norristown, Pennsylvania, 2 September 2014

PluroGen Therapeutics, Inc., leading solutions for wound, burn and skin care with its advanced PluroGel® Biomaterial surfactant products, announced today that, after a preliminary data review, the Company has achieved the positive objectives for its Phase II Clinical Trial in patients with mildly infected diabetic foot ulcers and has notified all clinical trial sites of the conclusion of the trial. PluroGen is now beginning the planning process for the Phase III clinical trial program, which has already been initially discussed with the FDA.

“Completion of patient enrollment in our Phase II clinical trial is another very significant and strategic milestone achievement. Our Phase II Trial was in patients with mildly infected diabetic foot ulcers, an indication that today has no approved topical antibiotic and is reported to be a \$2 billion market segment. Phase II is an important drug development milestone which moves PluroGen closer to market and adds real value to the Company and its shareholders.” commented Neal Koller, President and CEO of PluroGen.

**About PluroGen Therapeutics**

PluroGen Therapeutics, Inc. is a biotechnology company that provides clinically advanced topical anti-infective products for diabetic ulcers, chronic (nonhealing) wounds and burns. The company developed its core family of PluroGel® products by utilizing its patent-protected advanced PluroGel® Biomaterial. In working closely with doctors, nurses, patients and healthcare institutions, PluroGel® products have been routinely used with documented superior results on more than 14,000 patients in and outside of the USA. More information can be found on the company web site at [www.plurogen.com](http://www.plurogen.com). For PluroGen Investor Information please call +1 (610) 539-3670.

**Safe Harbor Statement:**

The statements in the press release that relate to PluroGen's (the company) expectations with regard to the future impact on the company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties which could cause the company's actual operating results, performance, business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.